Video

Experts Discuss Highly Anticipated Study Results Across Tumor Types

Author(s):

OncLive Staff

OncLive interviewed experts at the State of the Science Summits in July 2019 on highly anticipated clinical trial results across tumor types.

OncLive interviewed experts at the State of the Science Summits in July 2019 on highly anticipated clinical trial results across tumor types.

Related Videos
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD
Jonathan Wesley Riess, MD, MS, an associate professor at the University of California (UC) Davis
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Laura A. Huppert, MD
Polly Niravath, MD
Arvind N. Dasari, MD, MS
Charles E. Geyer, Jr., MD
Sattva S. Neelapu, MD
Related Content
Supriya Gupta, MD
January 9th 2025

Venetoclax Plus BTK Inhibitor–Based Combinations Represent Promising Avenue in CLL/SLL

MedNews Week
January 1st 2025

DESTINY-Breast06 Data Demonstrate the Role of T-DXd in HER2-Low and -Ultralow Breast Cancer: With Chandler Park, MD; and Guiseppe Curigliano, MD, PhD

Nirav N. Shah, MD
January 7th 2025

Novel BTK Degrader NX-5948 Yields High Response Rates in Pretreated CLL/SLL

MedNews Week
December 12th 2024

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

NSCLC | Image Credit: © Axel Kock – stock.adobe.com
January 7th 2025

Amivantamab Plus Lazertinib Improves OS in EGFR-Mutant Advanced NSCLC

Armin Ghobadi, MD
January 7th 2025

WT-7 Shows Acceptable Safety Profile in Relapsed/Refractory T-ALL/LBL